These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 24112812)

  • 21. First-line therapy for chronic myeloid leukemia: Past, present, and future.
    Pavlovsky C; Kantarjian H; Cortes JE
    Am J Hematol; 2009 May; 84(5):287-93. PubMed ID: 19306355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up.
    Fujisawa S; Nakamae H; Ogura M; Ishizawa K; Taniwaki M; Utsunomiya A; Matsue K; Takamatsu Y; Usuki K; Tanimoto M; Ishida Y; Akiyama H; Onishi S
    Int J Hematol; 2014 Feb; 99(2):141-53. PubMed ID: 24357015
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia.
    Radich JP
    Cancer; 2012 Jan; 118(2):300-11. PubMed ID: 21717440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
    Kantarjian H; Cortes J
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S37-42; quiz S43-S44. PubMed ID: 18397680
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.
    Irvine E; Williams C
    Pharmacotherapy; 2013 Aug; 33(8):868-81. PubMed ID: 23553655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of Dasatinib Versus Nilotinib as Upfront Therapy for Chronic Phase of Chronic Myeloid Leukemia in Qatar: A Cost-Effectiveness Analysis.
    Adel A; Abushanab D; Hamad A; Abdulla M; Izham M; Yassin M
    Cancer Control; 2021; 28():10732748211001796. PubMed ID: 33887995
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
    Hjorth-Hansen H; Stenke L; Söderlund S; Dreimane A; Ehrencrona H; Gedde-Dahl T; Gjertsen BT; Höglund M; Koskenvesa P; Lotfi K; Majeed W; Markevärn B; Ohm L; Olsson-Strömberg U; Remes K; Suominen M; Simonsson B; Porkka K; Mustjoki S; Richter J;
    Eur J Haematol; 2015 Mar; 94(3):243-50. PubMed ID: 25082346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.
    Kim WS; Kim D; Kim DW; Kweon IY; Kim SH; Goh HG; Park SH; Lee J
    Hematol Oncol; 2010 Jun; 28(2):82-8. PubMed ID: 19768693
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
    Rix U; Hantschel O; Dürnberger G; Remsing Rix LL; Planyavsky M; Fernbach NV; Kaupe I; Bennett KL; Valent P; Colinge J; Köcher T; Superti-Furga G
    Blood; 2007 Dec; 110(12):4055-63. PubMed ID: 17720881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase.
    Chuah CT; Nakamae H; Shen ZX; Bradley-Garelik MB; Kim DW
    Leuk Lymphoma; 2014 Sep; 55(9):2093-100. PubMed ID: 24289108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
    Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J
    Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib.
    Hughes TP; Saglio G; Kantarjian HM; Guilhot F; Niederwieser D; Rosti G; Nakaseko C; De Souza CA; Kalaycio ME; Meier S; Fan X; Menssen HD; Larson RA; Hochhaus A
    Blood; 2014 Feb; 123(9):1353-60. PubMed ID: 24335106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.
    Anderson KR; Chambers CR; Lam N; Yau PS; Cusano F; Savoie ML; Sheikh N
    J Oncol Pharm Pract; 2015 Feb; 21(1):19-25. PubMed ID: 24503243
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients.
    Hiwase DK; Yeung DT; White DL
    Expert Rev Hematol; 2011 Jun; 4(3):285-99. PubMed ID: 21668394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A critical review of trials of first-line BCR-ABL inhibitor treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
    Jabbour E; Lipton JH
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):646-56. PubMed ID: 24095296
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.
    Cornelison AM; Kantarjian H; Cortes J; Jabbour E
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(0 1):S101-10. PubMed ID: 22035738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
    Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
    DeAngelo DJ; Attar EC
    Leuk Lymphoma; 2010 Mar; 51(3):363-75. PubMed ID: 20038231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Tyrosine kinase inhibitors -  major change in the prognosis of chronic myeloid leukaemia].
    Klamová H
    Vnitr Lek; 2013 Jul; 59(7):624-6. PubMed ID: 23909271
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
    Kantarjian HM; Shah NP; Cortes JE; Baccarani M; Agarwal MB; Undurraga MS; Wang J; Ipiña JJ; Kim DW; Ogura M; Pavlovsky C; Junghanss C; Milone JH; Nicolini FE; Robak T; Van Droogenbroeck J; Vellenga E; Bradley-Garelik MB; Zhu C; Hochhaus A
    Blood; 2012 Feb; 119(5):1123-9. PubMed ID: 22160483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.